23andMe SPAC Presentation Deck

Balancing Growth With Profitability in Consumer and Research Services Note: Fiscal year ends March 31. Consumer and Research Services Investing in Our Future CRS Adjusted EBITDA ($ in M) ($86) FY19A $441 Gross Margin ($66) 23andMe Financials ($ in M, except for %) Revenue 44% FY20A $305 45% Sales & Marketing Expense $191 $111 ($9) FY21E $218 45% $44 ($10) FY22E $256 51% $69 Profitable Growth $26 FY23E $317 55% $76 $71 FY24E $400 58% $85 23and Me Confidential and Proprietary Information 32

View entire presentation